Kinepolis Group NV (0QV7)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 48.20 |
|---|---|
| 52-week range | 23.75 – 52.40 |
| Return, 1 month / 3 months | −5.5% / +25.0% |
| Return, 1 year / 3 years | +56.9% / +10.1% |
| Trend | Uptrend |
| RSI (14) | 43 |
| Volatility (1 year) | 27.2% |
| Worst drawdown (1 year) | -21.1% |
| Average daily value traded | 0.13M EUR |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kinepolis Group is a cinema operator based in Belgium that runs multiplex theatres showing films to general audiences. The company operates cinemas in several European countries and in North America, offering conventional and premium screens along with related services such as concessions and screen advertising. It also has activities in film distribution and cinema technology, serving moviegoers and advertising clients across its markets.
On this site Kinepolis Group NV appears as a stock on the London Exchange (UK), code 0QV7, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kinepolis Group NV (0QV7) trades on the London Exchange in UK. It last closed at EUR 48.20 on 22 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 584 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 56.9% and over the last three months it rose 25.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 37.7% | ||
| From 52-week high | -7.3% | ||
| Momentum | 93 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 25.0% | ||
| 6-month return | 63.7% | ||
| 12-month return, skipping the last month | 66.0% | ||
| Stability (higher is calmer) | 70 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.1% | ||
| Liquidity | 32 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.13M EUR | ||
| Zero-volume days | 11.7% | ||
| Income | 13 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.2% |
|---|---|
| 1 month | −5.5% |
| 3 months | +25.0% |
| 6 months | +63.7% |
| 1 year | +56.9% |
| 3 years | +10.1% |
| 5 years | −6.4% |
Signals
| 50-day / 200-day average | 48.13 / 35.01 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.4550 |
| 16 May 2025 | EUR 0.3850 |
| 13 May 2024 | EUR 0.3850 |
| 12 May 2023 | EUR 0.1820 |
| 10 May 2019 | EUR 0.6440 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.